Vecuronium Bromide

Sold as Norcuron. Every FDA application for this active ingredient: 1 branded and 12 generic.

As of Nov 15, 2026, FDA lists 13 applications for Vecuronium Bromide (sold as Norcuron), first approved Apr 30, 1984, with 1 new use approved and 0 published complete response letters.

First approved: Apr 30, 1984
Applications: 13
New uses approved: 1
Complete response letters: 0

Clinical Trials

5 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all


A Dose-Finding Study of Amogammadex Sodium for Reversing Vecuronium and Rocuronium-Induced Neuromuscular BlockadeReversing Vecuronium-Induced Neuromuscular Blockade in Patients Undergoing General Anesthesia Surgery, Reversing Rocuronium-Induced Neuromuscular Blockade in Patients Undergoing General Anesthesia Surgery · Amckaus PTY LTD.	Phase 2	Not yet recruiting	May 19, 2026
Effect of Opioid-Free vs Opioid-Based Anesthesia on Postoperative Pain and Emergence Agitation in Children Undergoing Cleft SurgeryCleft Lip Palate, Orofacial Cleft · Iva Smiljanić	Not applicable	Recruiting	Apr 29, 2026
Two Video Laryngoscopes (Laringocel® and C-MAC®) for First-Attempt Intubation in Adults Undergoing Elective SurgeryAirway Management, Intubation, Endotracheal · Mario Zamudio	Not applicable	Recruiting	Nov 20, 2025
GA + ESP vs. SA + ESP in Lumbar Decompression SurgeriesLumbar Disc Herniation, Lumbar Disc Disease · Hospital for Special Surgery, New York	Phase 3	Enrolling by invitation	Jul 6, 2022
Trial of Therapeutic Hypothermia in Patients With ARDSRespiratory Distress Syndrome, Adult · University of Maryland, Baltimore	Phase 2	Active, not recruiting	Sep 11, 2020

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history


Apr 30, 1984	NorcuronNDA 18776 · New molecular entity	Organon USA Inc	24	Discontinued
Aug 31, 1995	Vecuronium BromideANDA 74334	Watson Labs	22	Discontinued
Aug 23, 1999	Vecuronium BromideANDA 75218	Hikma	3	Discontinued
Aug 25, 1999	Vecuronium BromideANDA 74688	Meitheal	6	Marketed
Oct 21, 1999	Vecuronium BromideANDA 75164	Hospira	4	Marketed
Jun 13, 2000	Vecuronium BromideANDA 75549	Hikma	4	Marketed
Sep 11, 2001	Vecuronium BromideANDA 75558	Hospira	0	Discontinued
Dec 29, 2008	Vecuronium BromideANDA 78274	Sagent Pharms Inc	2	Marketed
Jun 17, 2009	Vecuronium BromideANDA 79001	Sun Pharm	2	Marketed
May 11, 2010	Vecuronium BromideANDA 90243	Mylan Labs Ltd	2	Marketed
May 26, 2016	Vecuronium BromideANDA 205390	Gland	1	Marketed
Dec 20, 2018	Vecuronium BromideANDA 206670	Eugia Pharma	0	Marketed
Jul 30, 2019	Vecuronium BromideANDA 203725	Hikma	1	Marketed

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA